Pharmaceutical composition comprising plasminogen and uses thereof
Pharmaceutical compositions comprising plasminogen or a biologically active variant thereof are disclosed. In an embodiment, the composition comprises a tonicity modifier, a bulking agent, and a stabilising agent and has a pH of about 3.0 to about 10.0. In another embodiment, the composition contains an amount of particles in suspension equal to or greater than 10 μm which is lower than 6000 particles per 100 ml, and preferably lower than 2000 particles per 100 ml. Uses of these compositions as a medicament is contemplated. Various therapeutic uses of these pharmaceutical compositions is also contemplated.
1. A method for treating plasminogen-deficiency and/or improving wound healing in a subject in need thereof, said method comprises administering to the subject an effective amount of a liquid pharmaceutical composition having an osmolality of 180 mOsm to 350 mOsm and a pH of 5 to 8 and comprising:
native human Glu-plasminogen, or a biologically active variant thereof having at least 90% amino acid sequence identity with native human Glu-plasminogen, in a concentration from 2 mg/ml to 60 mg/ml; and
a stabilising agent, which is arginine, an arginine salt, glycine or a glycine salt, in a concentration from 10 to 200 mM.
2. The method of claim 1 , wherein the wound is tympanic membrane perforation, a periodontal wound, or a diabetic ulcer.
3. The method of claim 1 , wherein the plasminogen deficiency is type I plasminogen deficiency.
4. The method of claim 1 , wherein the stabilising agent is arginine or an arginine salt.
5. The method of claim 1 , wherein the stabilising agent is glycine or a glycine salt.
6. The method of claim 1 , wherein the stabilising agent is in a concentration of 25 mM to 150 mM.
7. The method of claim 1 , wherein the composition further comprises sodium chloride.
8. The method of claim 7 , wherein the sodium chloride is present in a concentration of 10 mM to 100 mM.
9. The method of claim 1 , wherein the pH of the pharmaceutical composition is from 6.0 to 7.0.
10. The method of claim 9 , wherein the pharmaceutical composition comprises a citrate buffer.
11. The method of claim 1 , wherein the pH of the pharmaceutical composition is from 5.0 to 5.5.
12. The method of claim 11 , wherein the pharmaceutical composition comprises an acetate buffer.
13. The method of claim 1 , wherein the concentration of the native human Glu-plasminogen or biologically active variant thereof is from 5 mg/ml to 30 mg/ml.
14. The method of claim 1 , wherein the pharmaceutical composition comprises native human Glu-plasminogen.
15. The method of claim 1 , wherein the pharmaceutical composition is free of aprotinin.
16. The method of claim 1 , wherein the pharmaceutical composition comprises sucrose.
17. The method of claim 1 , wherein the pharmaceutical composition is administered intravenously.
18. The method of claim 1 , wherein the pharmaceutical composition is administered subcutaneously or intradermally.
19. The method of claim 18 , wherein the method is for improving wound healing in the subject, and wherein the pharmaceutical composition comprises an acetate buffer having a pH of 5.0 to 5.5 and:
5 mg/ml to 30 mg/ml native human Glu-plasminogen;
25 mM to 150 mM of arginine or an arginine salt; and
0 mM to 75 mM of sodium chloride.
20. The method of claim 17 , wherein the method is for treating type I plasminogen deficiency, and wherein the pharmaceutical composition comprises a citrate buffer having a pH of 6.0 to 7.0 and comprises:
5 mg/ml to 20 mg/ml native human Glu-plasminogen;
35 mM to 75 mM of sodium chloride;
25 mM to 75 mM of glycine or a glycine salt; and
from 54 to 108 mM of sucrose.